TTK Healthcare Limited (TTKHLTCARE) AI Stock Analysis

0 Followers

TTK Healthcare Limited

(NSE:TTKHLTCARE)

Select Model

Rating:54Neutral

Price Target:INR 924.00▼(-2.00% Downside)

Action:reiterated

Date:10/31/26

The score is held back primarily by sustained negative operating/free cash flow and recent margin pressure, despite a very conservative balance sheet. Technicals also remain weak with the stock trading below major moving averages and bearish momentum indicators. A reasonable P/E and small dividend provide partial support but do not outweigh the cash-flow and trend concerns.

Positive Factors

Conservative balance sheetVery low leverage gives TTK Healthcare substantial financial flexibility and reduces solvency pressure during operating volatility. A growing equity base and asset position can support investment in products, distribution, and healthcare opportunities without relying heavily on external borrowing.

Negative Factors

Sustained cash burnPersistent negative operating and free cash flow means reported earnings are not translating into cash generation. This reduces financial flexibility despite low debt and may constrain the company’s ability to fund growth, absorb working-capital demands, or return capital without relying on its balance-sheet resources.

TTK Healthcare Limited (TTKHLTCARE) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 13.55B
Dividend Yield: 1.06%
Average Volume (3M): 1,899
Price to Earnings (P/E): 4.8
Beta (1Y): 0.72
Revenue Growth: 11.29%
EPS Growth: 317.32%
Country: India
Employees: 1,478
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

TTK Healthcare Limited Business Overview & Revenue Model

Company Description

TTK Healthcare Limited is a diversified enterprise operating across multiple sectors in India and globally. Its extensive activities encompass animal welfare, offering veterinary therapeutic solutions and feed supplements. The human pharmaceuticals d...

How the Company Makes Money

TTK Healthcare primarily makes money by selling healthcare products and medical devices under its own brands and through institutional supply. Its revenue model is driven by: (1) Consumer healthcare sales: Revenue from branded consumer/OTC healthcare...

TTK Healthcare Limited Financial Statement Overview

Summary

Strong balance sheet with very low leverage and a growing equity base supports stability, but this is offset by sustained negative operating and free cash flow in 2023–2026 and a notable margin step-down in the latest year. Revenue growth persists but has slowed to low-single digits, and earnings durability appears less consistent due to an unusually strong (likely non-recurring) 2023 profit level.

Income Statement

62Positive

Balance Sheet

86Very Positive

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	9.37B	8.57B	8.73B	7.48B	7.25B	5.99B
Gross Profit	4.13B	2.80B	5.04B	4.07B	3.77B	3.09B
EBITDA	865.03M	261.76M	1.06B	999.35M	797.92M	412.65M
Net Income	2.77B	656.80M	816.57M	628.42M	6.40B	415.88M
Balance Sheet
Total Assets	16.51B	13.29B	12.81B	12.01B	11.70B	5.59B
Cash, Cash Equivalents and Short-Term Investments	10.52B	9.75B	8.55B	8.45B	8.47B	2.73B
Total Debt	283.05M	243.78M	242.19M	228.11M	273.29M	222.13M
Total Liabilities	3.05B	2.14B	2.16B	2.00B	2.17B	2.29B
Stockholders Equity	13.47B	11.15B	10.65B	10.01B	9.53B	3.30B
Cash Flow
Free Cash Flow	0	-269.50M	-168.16M	-153.27M	-377.75M	385.02M
Operating Cash Flow	0	-211.48M	-39.76M	-49.43M	-260.76M	449.96M
Investing Cash Flow	0	515.79M	201.03M	284.94M	329.59M	-305.47M
Financing Cash Flow	0	-175.56M	-180.81M	-219.11M	-124.26M	-51.77M

TTK Healthcare Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price942.85

Price Trends

50DMA1032.62Negative

100DMA1021.48Negative

200DMA955.31Positive

Market Momentum

MACD-28.71Positive

RSI45.78Neutral

STOCH20.16Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TTKHLTCARE, the sentiment is Neutral. The current price of 942.85 is below the 20-day moving average (MA) of 971.06, below the 50-day MA of 1032.62, and below the 200-day MA of 955.31, indicating a neutral trend. The MACD of -28.71 indicates Positive momentum. The RSI at 45.78 is Neutral, neither overbought nor oversold. The STOCH value of 20.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TTKHLTCARE.

TTK Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:TTKHLTCARE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ABBOTINDIA	81Outperform	INR 554.61B	34.20	―	2.01%	7.21%	9.54%
IN:CIPLA	79Outperform	INR 1.14T	39.26	―	2.06%	-0.74%	-46.77%
IN:GLAXO	68Neutral	INR 461.87B	39.24	―	2.15%	12.12%	20.03%
IN:SANOFI	65Neutral	INR 76.21B	20.73	―	3.75%	-5.74%	2.30%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:TTKHLTCARE	54Neutral	INR 13.50B	4.81	―	1.06%	11.29%	317.32%

* General Sector Average

Performance Comparison

IN:TTKHLTCARE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:TTKHLTCARE	TTK Healthcare Limited	942.85	-176.70	-15.78%
IN:ABBOTINDIA	Abbott India Limited	26603.60	-1952.37	-6.84%
IN:CIPLA	Cipla Ltd	1410.00	-107.40	-7.08%
IN:GLAXO	GlaxoSmithKline Pharmaceuticals Limited	2655.30	238.78	9.88%
IN:SANOFI	Sanofi India Limited	3284.50	-1140.35	-25.77%
IN:SANOFICONR	Sanofi Consumer Healthcare India Limited	3538.75	-1213.11	-25.53%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

TTK Healthcare Limited AI Stock Analysis